Search Results 321-330 of 18829 for prostate cancer

  1. A Study to Compare Docetaxel/Prednisone to Docetaxel/Prednisone Combined with OGX-011 in Men with Prostate Cancer - Mayo Clinic

    Clinical Trials · A Study to Compare Docetaxel/Prednisone to Docetaxel/Prednisone Combined with OGX-011 in Men with Prostate Cancer · More about research at Mayo ...

  2. A Study of Single Patient Investigational Drug CPI-613 for Use in Treatment-Refractory, Metastatic Prostate Cancer - Mayo Clinic

    About this study. This is a single patient study of an investigational drug CPI-613 for treatment of metastatic prostate cancer. Participation eligibility.

  3. Prostate Tumor Ablation Clinical Trials - Mayo Clinic Research

    The purpose of this study is to determine the safety of the NanoKnife treatment in prostate cancer tissue when used in a low and intermediate risk patient ...

  4. A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) - Mayo Clinic

    A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate ...

  5. Publications - Cassandra N. Moore, M.D. - Mayo Clinic

    ... prostate cancer. Prostate Cancer Prostatic Dis. 2022 Sep; 25 (3):479-483 Epub 2021 July 22. View PubMed; Nafissi NN, Kosiorek HE, Butterfield RJ, Moore C, Ho ...

  6. Publications - Brian J. Davis, M.D., Ph.D. - Mayo Clinic

    Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Prostate Cancer Prostatic Dis. 2021 ...

  7. Prostate cancer / exercise and the heart / headaches - Mayo Clinic News Network

    Prostate cancer / exercise and the heart / headaches. 00:00. |. Prostate cancer / exercise and the heart / headaches. Feb. 22, 2020. Show Coverart. Donate. + ...

  8. Optimal sequencing of commonly used medications for treatment of metastatic castration-resistant prostate cancer - Mayo Clinic

    Unfortunately, most men in this situation will go on to develop metastatic castration-resistant prostate cancer (mCRPC) and require secondary systemic therapy.

  9. Men’s Cancer Conference 2007

    Topics include bone health, nutrition, PSA monitoring, erectile dysfunction and incontinence. What to Expect from Prostate Cancer Treatment. Bradley Leibovich, ...

  10. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer - Mayo Clinic

    ... prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease. Participation eligibility.